Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, reported positive top-line results from the phase IIb SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the company’s first-in-class, oral Selective Inhibitor of Nuclear Export compound, in patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
